BioNTech SE acquires CureVac
BioNTech SE agreed to acquire CureVac. Reported deal value: Undisclosed. Status: Announced. Sector: Healthcare. Target headquarters context: Tuebingen, Baden-Wuerttemberg, Germany.
This page summarizes publicly available information about the transaction as of 2026-01-03. Figures and status may change as filings and press coverage update.
Should investors sell immediately? Or is it worth buying CureVac ? Acquiring Entity: BioNTech SE Stake Secured: Roughly 86.75% of CureVac shares Offer Closure: December 18, 20 25 Squeeze-Out Execution: January 20 26 Final Outcome: Delisting of CureVac equity Share Price Dynamics Shift from Fundamentals to Mechanics CureVac stock performance has decoupled from operational developments
Deal timeline
This transaction is classified in Healthcare. Figures and status may change as sources update.